Founded in 2013 by Dr. Claresa Levetan, Perle Bioscience is dedicated to finding original treatments for type 1 diabetes with the ultimate goal of eliminating the disease all together. Perle has discovered novel human beta regeneration peptides for which has been issued “composition of matter” patents. Perle’s total IP portfolio comprises 12 issued and pending patents all in the diabetes space. Perle’s intellectual property is established around the In Vivo use of proton pump inhibitors combined with immune tolerance agents, with the ultimate goal of eliminating any injections for the patients. To learn more, please visit us at www.PerleBioscience.com.
Dr. Fiorini received his Ph.D. in Immunology and Microbiology from the Medical University of South Carolina (MUSC) in Charleston in 2005. He later received his M.B.A. from the Citadel in 2007 and a Masters of Hospital Administration (M.H.A.) from the Medical University in 2008.
In 2010, Dr. Fiorini founded Immunologix, Inc. a company built on a specialized platform that transformed naïve human B-cells to produce 100% human monoclonal antibodies against multiple target antigens. From the company’s commencement in September 2009 through its acquisition by Intrexon Corporation (NYSE: XON) in October 2011, he served as the Founder and Chief Operating Officer. After the acquisition by Intrexon, he served as the Vice President of Antibody Development until transitioning into the role of Vice President of Therapeutics Business Development working directly under Intrexon CEO, Randal J. (R.J.) Kirk.
Dr. Fiorini left Intrexon in April 2013 to spend more time looking for “the next” start-up opportunity, building his biotech consulting company and spending time with his family. Dr. Fiorini joined Perle Bioscience as President and CEO in February 2014.

Category: Nonprofits & Activism
Uploaded by: Diabetes Hands Foundation
Hosted: youtube